EYPT insider trading
NasdaqGM HealthcareEyePoint, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Company website: eyepoint.bio
EYPT insider activity at a glance
FilingIQ has scored 387 insider transactions for EYPT since Apr 20, 2018. The most recent filing in our index is dated Apr 17, 2026.
Across the full history, 45 open-market purchases
and 64 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EYPT insider trades is 56.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EYPT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding EYPT
Frequently asked
- How many insider trades does FilingIQ track for EYPT?
- FilingIQ tracks 387 Form 4 insider transactions for EYPT (EyePoint, Inc.), covering filings from Apr 20, 2018 onwards. 18 of those were filed in the last 90 days.
- Are EYPT insiders net buyers or net sellers?
- Across the full Form 4 history for EYPT, 45 transactions (12%) were open-market purchases and 64 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EYPT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is EYPT in?
- EyePoint, Inc. (EYPT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.25B.
Methodology & sources
Every EYPT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.